Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML

Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients Followed for AML Treated With Oral Targeted Therapy

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05309018

Acronym

LAMIPA

Enrollment

Registered

2022-04-04

Start date

2024-05-15

Completion date

2024-12-15

Last updated

2024-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloid Leukemia

Keywords

Advanced Practice Nurse, Acute Myeloid Leukemia,

Brief summary

Advanced Practice Nurse (APN) is a new contributor in the French healthcare system. APN is part of a multidisciplinary team and aim to monitor patients under the coordination of the doctor particularly in onco-hematology. The aim of the study is to describe the different perceptions and expectations of APN monitoring according to patients with acute myeloid leukemia (AML) and their care team. This study will involve 10 patients, recruited over a provisional period of 5 months and 25 member of care team. Patients and their care team will be asked about their perceptions and expectations of APN participation in (AML monitoring) during a semi-structured interviews.

Interventions

OTHERInterviews

Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with AML * Treated with a new targeted oral therapy as monotherapy or in combination: * Venetoclax\* in combination with ivosidenib (IDH1 inhibitor) * Onureg\* (azacitin: pyrimidine analogue) * Venetoclax (BCL-2 protein inhibitor) in combination with subcutaneous azacitin * Whose follow-up is provided alternately by a hematologist and an IPA. * Affiliated to a social security scheme

Exclusion criteria

* Moderate or severe cognitive impairment * Language barrier * Other communication disorders

Design outcomes

Primary

Measure	Time frame	Description
Perception of patient	Within 1 month	Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to patient.

Secondary

Measure	Time frame	Description
Perception of care team	Within 1 month	Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to care team.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026